CGEM vs. SRRK, BCRX, AUTL, XNCR, IMTX, PROK, FDMT, VIR, RLAY, and TARS
Should you be buying Cullinan Oncology stock or one of its competitors? The main competitors of Cullinan Oncology include Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Xencor (XNCR), Immatics (IMTX), ProKidney (PROK), 4D Molecular Therapeutics (FDMT), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "medical" sector.
Scholar Rock (NASDAQ:SRRK) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Scholar Rock has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Cullinan Oncology has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500.
Scholar Rock received 116 more outperform votes than Cullinan Oncology when rated by MarketBeat users. However, 78.05% of users gave Cullinan Oncology an outperform vote while only 63.25% of users gave Scholar Rock an outperform vote.
Scholar Rock's return on equity of -32.11% beat Cullinan Oncology's return on equity.
91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Oncology shares are owned by institutional investors. 26.2% of Scholar Rock shares are owned by insiders. Comparatively, 8.8% of Cullinan Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Scholar Rock had 5 more articles in the media than Cullinan Oncology. MarketBeat recorded 13 mentions for Scholar Rock and 8 mentions for Cullinan Oncology. Scholar Rock's average media sentiment score of 0.73 beat Cullinan Oncology's score of 0.12 indicating that Cullinan Oncology is being referred to more favorably in the news media.
Cullinan Oncology has lower revenue, but higher earnings than Scholar Rock. Cullinan Oncology is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.
Scholar Rock presently has a consensus price target of $25.17, indicating a potential upside of 79.25%. Cullinan Oncology has a consensus price target of $31.00, indicating a potential upside of 16.02%. Given Cullinan Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Scholar Rock is more favorable than Cullinan Oncology.
Summary
Scholar Rock beats Cullinan Oncology on 11 of the 18 factors compared between the two stocks.
Get Cullinan Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Oncology Competitors List
Related Companies and Tools
